Comparing givinostat and hydroxyurea for treating polycythemia vera

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to evaluate the efficacy and safety of givinostat compared to hydroxyurea in patients with high-risk polycythemia vera who are positive for the JAK2V617F mutation. Participants must have been diagnosed with polycythemia vera within the last three years and meet specific criteria indicating a high risk for thrombosis. The study will involve randomization of eligible patients to receive either givinostat or hydroxyurea and will monitor their health outcomes over time.

Why it matters

Who can join: the full rules

Core Treatment - Inclusion Criteria:

* Patients must have been diagnosed with PV according to the 2016 WHO criteria before randomization
* Patients must have JAK2V617F-positive disease
* Patients with PV must meet the definition of HR for thrombosis (i.e., HR) within 3 years before screening as follows:

  * Age ≥ 60 years, and/or
  * Prior thrombosis.
* Patients must be in need of treatment at screening, defined by the presence of at least one of the following:

  * HCT ≥ 45% or HCT \< 45% with at least 1 phlebotomy performed in the 3 months before screening, or
  * WBC count \> 10 × 109/L, or
  * PLT count \> 400 × 109/L.
* Patients must have normalized HCT (i.e., HCT \< 45%) at randomization

Extended Treatment - Inclusion Criteria

* Patients must have completed the Week 48 visit of the DSC/08/2357/32 core treatment phase and:

  1. if the patient received givinostat, a complete hematological response (CHR) at Week 48 shall be achieved
  2. if the patient received HU, did not achieve a CHR (see above for the definition) at Week 48

     Core Treatment phase - Exclusion Criteria
* Patients pre-treated with HU with a documented history of resistance or intolerance to HU defined by the original ELN criteria
* Patients with a QTcF value of \> 450 msec for males and \> 460 msec for females at the Screening visit (as the mean of 3 consecutive readings 5 minutes apart in the event a first ECG demonstrates a prolonged QTcF interval); congenital or acquired history of QTc prolongation or ventricular arrhythmias, at the Screening visit
* Splanchnic thrombosis and/or thrombosis of the cerebral venous sinuses and/or splenectomy in the medical history
* Patients with clinically significant cardiovascular disease
* Patients with myocardial infarction, stroke or unstable angina within the 6 months prior to screening.
* Patients with inadequate liver or renal function at screening
* Uncontrolled hypertriglyceridemia at screening, i.e., triglycerides ˃ 1.5 × ULN
* Previous treatment with a JAK2 or HDAC inhibitor or 32-phosphorus (radioactive isotope) therapy.
* Patients being treated concurrently with any investigational agent or prior participation in an interventional clinical study within the 30 days prior to screening or within 5 half-lives of the investigational product, whichever is longer.
* Pregnant or nursing women

Extended treatment phase - Exclusion criteria

* For patients randomized to givinostat in the core treatment phase - Patients with a QTcF value at Week 48 of \> 500 msec
* For patients randomized to HU in the core treatment phase:

  * PLT count ≤ 150 × 109/L at Week 48
  * ANC \< 1.2 × 109/L at Week 48
  * Uncontrolled hypertriglyceridemia at Week 48
  * Patients with a QTcF value at Week 48 of \> 450 msec for males and \> 460 msec for female

Where it's running

• Emad Ibrahim, MD, Inc
  Redlands, California, United States Recruiting
• US Oncology Inc
  Englewood, Colorado, United States Recruiting
• American Oncology Partners of Maryland, PA
  Bethesda, Maryland, United States Recruiting
• Icahn School of Medicine at Mount Sinai
  New York, New York, United States Recruiting
• University of North Carolina at Chapel Hill
  Chapel Hill, North Carolina, United States Recruiting
• The Cleveland Clinic Foundation
  Cleveland, Ohio, United States Recruiting

+40 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Study coordinator: Maurizio Caserini
• Email: patientadvocacy@italfarmacogroup.com
• Phone: +39 02 6443 1

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• MPNdpoint: Long-term Look at Philadelphia-negative Myeloproliferative Neoplasms

  This study tests how outcomes differ for patients 16 and older with polycythemia vera, essential thrombocythemia, or myelofibrosis by collecting and analyzing clinical and treatment data.

  Recruiting Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · Milan · NCT07863466

• Test of bomedemstat for polycythemia vera in adults

  This study tests bomedemstat (MK-3543) to see if it helps people with polycythemia vera reach healthier blood counts compared with standard treatments.

  Recruiting at 5 sites Phase 2/3 Merck Sharp & Dohme LLC · Newark, Delaware and 4 other locations · NCT07722611

• Rusfertide in Japanese adults with polycythemia vera

  This study tests rusfertide in Japanese adults with polycythemia vera to see if it helps keep hematocrit under control and reduce the need for blood removal.

  Recruiting at 8 sites Phase 2 Takeda · Nagoya, Aichi-ken and 8 other locations · NCT07648030

• Sapablursen added to standard care for people with polycythemia vera

  This trial will test whether adding sapablursen to standard therapy can reduce the need for phlebotomy in people with polycythemia vera who remain phlebotomy-dependent.

  Recruiting at 38 sites Phase 3 Ono Pharmaceutical Co., Ltd. · Orange, California and 37 other locations · NCT07429266

• MPN PROGRESSion Registry — tracking symptoms, treatments, and disease progression in people with MPNs.

  Track long-term symptoms, treatments, and disease progression in adults with myeloproliferative neoplasms to see how these conditions evolve over time.

  Recruiting at 2 sites MPN Research Foundation · Chicago, Illinois and 1 other locations · NCT07362225

• ELN multicenter analysis of phenotypic evolution and clinical outcomes

  This study tries to find features linked to JAK2V617F-positive essential thrombocythemia (ET) patients who later developed polycythemia vera (PV) by comparing them with matched ET patients who did not progress and with patients diagnosed with de novo PV.

  Recruiting at 10 sites FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS · Rochester, Minnesota and 23 other locations · NCT07203768

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.